Objective: To study the clinical pathological features of patients with relapsed diffuse large B-celllymphoma (DLBCL) and to provide evidence for early clinical screening of recurrent cases. Methods: The clinical and pathological data of the 20 patients, who had relapsed DLBCL (relapsed group) and were admitted to the First Affiliated Hospital of Nanjing Medical University from January 2015 to December 2019, were included. Meanwhile, other 34 patients with DLBCL who had achieved complete response (CR) for 36 months or more (CR group) were used as controls.Statistical methods were used to retrospectively analyze the differences in general conditions, clinical characteristics, lab resultsand pathological features between the two groups. Results: Clinically, there were 6 males and 14 females with a median age of 55.5 (33-85) years in the relapsed group and 14 males and 20 females with a median age of 53 (15-89) years in the CR group. The relapsed and CR groups had significant difference in Ann Arbor stage (P=0.001), International Prognostic Index score (P=0.006), primary lesions (P=0.003), extranodal involvement (P=0.002), and hepatitis B viral infection (P=0.046), β2-MG level (P=0.029), LDH level (P=0.005) and CRP level (P=0.006), while the age (P=0.732), gender (P=0.416), ECOG score (P=0.248), B symptoms (P=0.511), the presence of hypoalbuminemia (P=0.279), anemia (P=0.983) and A/G(P=0.416) showed no statistical difference.Pathologically, compared with the CR group, the relapsed group was mostly non-GCB type (85% vs. 59%,P=0.048), with a higher CD5 positive rate (25% vs.3%,P=0.014) and a lower bcl-6 positive rate (60% vs. 88%,P=0.017), while the expression of Ki-67, CD10, bcl-2, MUM1, CD20 and PAX5 was not different between the two groups. Conclusion: Most of the patients with relapsed DLBCL are non-GCB type. The patients with CD5 positivity, stage III-IV, International Prognostic Index score 3-5, nodal origin, often involving>1 extranodal organ, abnormally elevated LDH, CRP and β2-MG level, and HBV infection are more likely to relapse.
目的： 探讨复发性弥漫性大B细胞淋巴瘤（DLBCL）的临床病理特征，为临床早期筛选复发性患者及评估预后提供依据。 方法： 收集2015年1月至2019年12月南京医科大学第一附属医院收治的20例复发性DLBCL患者（复发组）的临床与病理资料，同时以同期治疗后达完全缓解且无进展生存期≥36个月的34例DLBCL患者组（CR组）作为对照，分析两组患者的一般情况、临床特点、实验室指标及病理特征等方面的差异。 结果： 临床方面，复发组男性6例，女性14例，中位发病年龄55.5（33~85）岁；CR组男性14例，女性20例，中位发病年龄53（15~89）岁。复发组与CR组在Ann Arbor分期（P=0.001）、国际预后指数（IPI）评分（P=0.006）、原发灶（P=0.003）、结外受累数（P=0.002）、乙型肝炎病毒（HBV）感染（P=0.046）、β2微球蛋白水平（P=0.029）、乳酸脱氢酶（LDH）水平（P=0.005）及C反应蛋白（CRP）水平（P=0.006）等方面差异具有统计学意义，而年龄（P=0.732）、性别（P=0.416）、体力状态评分（P=0.248）、是否伴随B症状（P=0.511）、是否存在低白蛋白血症（P=0.279）及贫血（P=0.983）、A/G值（P=0.416）等方面差异无统计学意义。病理方面，复发组与CR组相比，分型多为非生发中心B细胞型（GCB型，85%∶59%，P=0.048），CD5阳性率更高（25%∶3%，P=0.014），bcl-6阳性率较低（60%∶88%，P=0.017），而Ki-67、CD10、bcl-2、MUM1、CD20、PAX5表达差异无明显统计学意义（P>0.05）。 结论： 复发性DLBCL患者多为非GCB型，以下指标提示患者更易出现复发：CD5阳性、分期Ⅲ~Ⅳ期、IPI评分3~5分、结内起源、常累及多处结外器官、异常增高的LDH、CRP及β2微球蛋白水平、伴随HBV感染者。.
Keywords: Lymphoma, B-cell; Pathology, clinical; Recurrence.